IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
Commentary: Psoriasis comprehensive review
Lars Iversen, MD, DMSc
Aarhus University Hospital
Aarhus, Denmark
IPC Board Member
PUBLICATION
Psoriasis. Griffiths C, Armstrong A, Gudjonsson J, Barker J. Lancet. vol. 397. no. 10281. 2021 Apr; 397: 1301–15. doi: 10.1016/s0140-6736(20)32549-6.
COMMENTARY
In the April 2021 issue of the Lancet, four of our esteemed colleagues in the IPC published an updated and comprehensive review of the current pieces of knowledge on psoriasis.
It is a very well-written review covering all aspects of psoriasis spanning from epidemiology and pathophysiology to clinical presentation, associated diseases, and the management of psoriasis. Alongside an update of the most recently published literature in the field of psoriasis, the manuscript is also accompanied by clear clinical pictures, figures that elegantly explain the pathogenesis of psoriasis, and tables that provide a good overview of the different treatment options.
The review is up-to-date and discusses the current knowledge and challenges in managing psoriasis during the SARS-CoV-2 pandemic and nicely points out future directions of psoriasis research by highlighting unresolved questions, new developments, and unmet medical needs. Because of the comprehensive nature of this manuscript, it appeals to those who want to gain an overview of the various aspects of psoriasis and those who are searching for an in-depth understanding of specific aspects of psoriasis and its subtypes such as their different pathophysiologies.
This manuscript will undoubtedly serve as a critical reference paper in the field of psoriasis in the coming years.
Categories
Recent Posts
What Comes Next in Psoriasis Treatment: A Look at the Current Pipeline
When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most
Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target
Also Read
What Comes Next in Psoriasis Treatment: A Look at the Current Pipeline
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most
Can a psoriasis patient with cancer still receive biologic therapy? IPC’s newest manuscript gives dermatologists and oncologists a shared, evidence-based answer, including which therapies to favor, which to avoid, and why the two specialties need to decide together.
Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target
In this article, IPC Board Member Lluís Puig, MD, PhD, gives his expert commentary on two randomized trials showing that ixekizumab plus tirzepatide outperforms ixekizumab alone for skin clearance, joint control, and weight loss in psoriasis and PsA.
Subscribe to the IPC Newsletter